Related Experiment Video

Updated: Sep 4, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.0K

Apatinib: A Novel Antiangiogenic Drug in Monotherapy or Combination Immunotherapy for Digestive System Malignancies

Haosheng Li1,2, Haiyan Huang1,2, Tao Zhang1,2

  • 1Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Frontiers in Immunology
|July 18, 2022
PubMed

Insights

Apatinib, a targeted antiangiogenic drug, shows promise in treating advanced digestive cancers by inhibiting tumor growth and angiogenesis. Clinical trials indicate it improves survival, offering a new option for chemotherapy-refractory patients.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Digestive system malignancies are a leading cause of cancer mortality.
  • Angiogenesis is crucial for tumor progression and metastasis.
  • Targeted therapies offer new treatment avenues for advanced cancers.

Purpose of the Study:

  • To review the pharmacological properties of apatinib.
  • To summarize the clinical applications of apatinib in advanced digestive cancers.
  • To explore the molecular mechanisms and future potential of apatinib.

Main Methods:

  • Review of pharmacological data and clinical trial results for apatinib.
  • Analysis of molecular mechanisms including antiangiogenic, apoptosis-inducing, and autophagy-inducing properties.
  • Evaluation of apatinib's efficacy in chemotherapy-refractory patients with advanced digestive system cancer.

Main Results:

  • Apatinib targets vascular endothelial growth factor receptor-2, inhibiting tumor angiogenesis and proliferation.
  • Clinical trials show apatinib prolongs progression-free and overall survival in advanced gastric and liver cancers.
  • Apatinib demonstrates synergistic effects with immunotherapy in other advanced cancers.

Conclusions:

  • Apatinib is a promising agent for advanced digestive system cancers, with potential antiangiogenic, apoptosis-inducing, and autophagy-inducing mechanisms.
  • Apatinib monotherapy or combination immunotherapy represents an optimal future treatment strategy for digestive malignancies.
  • Further research into apatinib's molecular pathways can optimize its clinical use.
Keywords:
Apatinibangiogenesisdigestive system malignanciesimmunotherapytumor microenvironment

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.9K
Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry08:30

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

12.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
652
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
258